News

These are the drugs that lose their U.S. patents in 2025: most are in common use across the country by millions of people
As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for ...
Pharmabiz7h
Bayer seeks EMA approval for aflibercept 8 mg for treatment of retinal vein occlusion
Bayer seeks EMA approval for aflibercept 8 mg for treatment of retinal vein occlusion: Berlin Thursday, April 10, 2025, 16:00 Hrs [IST] Bayer has submitted an application to the E ...
Celltrion wins 3 biosimilar approvals in Australia, eyes Oceania growth
South Korea’s pharmaceutical giant Celltrion said Thursday it has received regulatory approvals for three biosimilars in ...
Fierce Biotech6h
Opthea lays off 65% of staff after back-to-back phase 3 eye disease flops
Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech ...
KED Global9h
Celltrion wins Australian approval for eye, bone disease biosimilars
Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilars: Eydenzel ...